Obesity Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Obesity Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Report Format: PDF+Excel | Report ID: SR112026A27912

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
2.5       Forecasting Methodology
3 Executive Summary
4 Obesity - Introduction

    4.1 Overview
    4.2 Regulatory Process
    4.3 Epidemiology (2020-2025) and Forecast (2026-2036​)
    4.4 Market Overview (2020-2025) and Forecast (2026-2036​)
    4.5 Competitive Intelligence
5 Obesity - Disease Overview
    5.1    Introduction
    5.2    Symptoms and Diagnosis
    5.3    Pathophysiology
    5.4    Causes and Risk Factors
    5.5    Treatment
6 Patient Journey
7 Obesity - Epidemiology and Patient Population
    7.1    Epidemiology - Key Insights    
    7.2    Epidemiology Scenario - Top 7 Markets
   
       7.2.1 Epidemiology Scenario (​2020-2025​)     
           7.2.2 Epidemiology Forecast (​2026-2036​)    
           7.2.3 Epidemiology by Age (​2020-2036​)
           7.2.4 Epidemiology by Gender (​2020-2036​)    
           7.2.5 Epidemiology by Type (​2020-2036​)    
           7.2.6 Diagnosed Cases (​2020-2036​)
           7.2.7 Patient Pool/Treated Cases (​2020-2036​)    
    7.3    Epidemiology Scenario - United States    
        7.3.1 Epidemiology Scenario (​2020-2025​)    
        7.3.2 Epidemiology Forecast (​2026-2036​)    
        7.3.3 Epidemiology by Age (​2020-2036​)    
        7.3.4 Epidemiology by Gender (​2020-2036​)
        7.3.5 Epidemiology by Type (​2020-2036​)    
        7.3.6 Diagnosed Cases (​2020-2036​)
        7.3.7 Patient Pool/Treated Cases (​2020-2036​)
    7.4    Epidemiology Scenario - Germany    
        7.4.1 Epidemiology Scenario (​2020-2025​)    
        7.4.2 Epidemiology Forecast (​2026-2036​)    
        7.4.3 Epidemiology by Age (​2020-2036​)
    7.4.4 Epidemiology by Gender (​2020-2036​)
        7.4.5 Epidemiology by Type (​2020-2036​)    
        7.4.6 Diagnosed Cases (​2020-2036​)
        7.4.7 Patient Pool/Treated Cases (​2020-2036​)
     7.5    Epidemiology Scenario - France            
        7.5.1 Epidemiology Scenario (​2020-2025​)
        7.5.2 Epidemiology Forecast (​2026-2036​)
        7.5.3 Epidemiology by Age (​2020-2036​)
    7.5.4 Epidemiology by Gender (​2020-2036​)
       7.5.5 Epidemiology by Type (​2020-2036​)    
              7.5.6 Diagnosed Cases (​2020-2036​)
             7.5.7 Patient Pool/Treated Cases (​2020-2036​)
    7.6     Epidemiology Scenario - United Kingdom
        7.6.1 Epidemiology Scenario (​2020-2025​)    
        7.6.2 Epidemiology Forecast (​2026-2036​)    
        7.6.3 Epidemiology by Age (​2020-2036​)    
        7.6.4 Epidemiology by Gender (​2020-2036​)    
        7.6.5 Epidemiology by Type (​2020-2036​)    
        7.6.6 Diagnosed Cases (​2020-2036​)
        7.6.7 Patient Pool/Treated Cases (​2020-2036​)    
    7.7    Epidemiology Scenario - Italy    
        7.7.1 Epidemiology Scenario (​2020-2025​)    
        7.7.2 Epidemiology Forecast (​2026-2036​)    
        7.7.3 Epidemiology by Age (​2020-2036​)    
        7.7.4 Epidemiology by Gender (​2020-2036​)    
        7.7.5 Epidemiology by Type (​2020-2036​)    
        7.7.6 Diagnosed Cases (​2020-2036​)
        7.7.7 Patient Pool/Treated Cases (​2020-2036​)
    7.8    Epidemiology Scenario - Spain    
        7.8.1 Epidemiology Scenario (​2020-2025​)    
        7.8.2 Epidemiology Forecast (​2026-2036​)    
        7.8.3 Epidemiology by Age (​2020-2036​)    
        7.8.4 Epidemiology by Gender (​2020-2036​)    
        7.8.5 Epidemiology by Type (​2020-2036​)    
        7.8.6 Diagnosed Cases (​2020-2036​)
        7.8.7 Patient Pool/Treated Cases (​2020-2036​)
    7.9    Epidemiology Scenario - Japan    
        7.9.1 Epidemiology Scenario (​2020-2025​)    
        7.9.2 Epidemiology Forecast (​2026-2036​)    
        7.9.3 Epidemiology by Age (​2020-2036​)
        7.9.4 Epidemiology by Gender (​2020-2036​)
        7.9.5 Epidemiology by Type (​2020-2036​)    
        7.9.6 Diagnosed Cases (​2020-2036​)
        7.9.7 Patient Pool/Treated Cases (​2020-2036​)
8 Obesity Treatment - Treatment Algorithm, Guidelines, and Medical Practices
    8.1    Guidelines, Management and Treatment
    8.2    Treatment Algorithm    
9 Obesity Treatment - Unmet Needs
10 Obesity Treatment - Key Endpoints of Treatment
11 Obesity Treatment - Marketed Products    
11.1 List of Obesity Treatment - Marketed Drugs Across the Top 7 Markets    
   
11.1.1 Xenical (Orlistat) - Roche
           11.1.1.1 Drug Overview    
           11.1.1.2 Mechanism of Action    
           11.1.1.3 Clinical Trial Results    
           11.1.1.4 Safety and Efficacy
           11.1.1.5 Regulatory Status    
11.1.2 Qsymia (Phentermine/topiramate) - VIVUS            
           11.1.2.1 Drug Overview    
           11.1.2.2 Mechanism of Action    
           11.1.2.3 Clinical Trial Results    
            11.1.2.4 Safety and Efficacy
            11.1.2.5 Regulatory Status
11.1.3 Contrave (Bupropion/naltrexone) - Currax Pharma
               11.1.3.1 Drug Overview    
               11.1.3.2 Mechanism of Action    
               11.1.3.3 Clinical Trial Results    
               11.1.3.4 Safety and Efficacy
               11.1.3.5 Regulatory Status
11.1.4 Saxenda (Liraglutide) - Novo Nordisk
                11.1.4.1 Drug Overview    
                11.1.4.2 Mechanism of Action    
                11.1.4.3 Clinical Trial Results    
                11.1.4.4 Safety and Efficacy
                11.1.4.5 Regulatory Status
11.1.5 Wegovy (Semaglutide) - Novo Nordisk
                 11.1.5.1 Drug Overview    
                11.1.5.2 Mechanism of Action    
                11.1.5.3 Clinical Trial Results    
                11.1.5.4 Safety and Efficacy
                11.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Obesity Treatment - Pipeline Products
      12.1 List of Obesity Treatment Pipeline Drugs Across the Top 7 Markets   
         12.1.1 Orforglipron (LY3502970) - Eli Lilly and Company

                12.1.1.1 Drug Overview
                12.1.1.2 Mechanism of Action
                12.1.1.3 Clinical Trial Results
                12.1.1.4 Safety and Efficacy  
                12.1.1.5 Regulatory Status
         12.1.2 Survodutide - Boehringer Ingelheim
                12.1.2.1 Drug Overview
                12.1.2.2 Mechanism of Action
                12.1.2.3 Clinical Trial Results
                12.1.2.4 Safety and Efficacy
                12.1.2.5 Regulatory Status
         12.1.3 CT 388 - Roche
                12.1.3.1 Drug Overview
                12.1.3.2 Mechanism of Action
                12.1.3.3 Clinical Trial Results
                12.1.3.4 Safety and Efficacy
                12.1.3.5 Regulatory Status
        12.1.4 LY3437943 (Retatrutide) - Eli Lilly and Company
                12.1.4.1 Drug Overview
                12.1.4.2 Mechanism of Action
                12.1.4.3 Clinical Trial Results
                12.1.4.4 Safety and Efficacy
                12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13 Obesity Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs    
14 Obesity Treatment – Clinical Trial Landscape

    14.1 Drugs by Status
    14.2 Drugs by Phase
    14.3 Drugs by Route of Administration
    14.4 Key Regulatory Events    
15 Obesity Treatment Market Scenario    
  15.1    Market Scenario - Key Insights    
  15.2    Market Scenario - Top 7 Markets
 
         15.2.1 Obesity Treatment - Market Size         
                  15.2.1.1 Market Size (2020-2025)    
                  15.2.1.2 Market Forecast (2026-2036​)
         15.2.2 Obesity Treatment - Market Size by Therapies     
                  15.2.2.1 Market Size by Therapies (2020-2025)
                  15.2.2.2 Market Forecast by Therapies (2026-2036​)
 15.3    Market Scenario - United States    
        15.3.1 Obesity Treatment - Market Size
                  15.3.1.1 Market Size (2020-2025)    
                 15.3.1.2 Market Forecast (2026-2036​)
        15.3.2 Obesity Treatment- Market Size by Therapies
                 15.3.2.1 Market Size by Therapies (2020-2025)                 
                 15.3.2.2 Market Forecast by Therapies (2026-2036​)    
        15.3.3 Obesity Treatment- Access and Reimbursement Overview
   15.4    Market Scenario - Germany    
          15.4.1 Obesity Treatment - Market Size    
                 15.4.1.1 Market Size (2020-2025)    
                 15.4.1.2 Market Forecast (2026-2036​)    
        15.4.2 Obesity Treatment- Market Size by Therapies
                 15.4.2.1 Market Size by Therapies (2020-2025)                        
                15.4.2.2 Market Forecast by Therapies (2026-2036​)
        15.4.3 Obesity Treatment- Access and Reimbursement Overview                
   15.5    Market Scenario - France    
         15.5.1 Obesity Treatment - Market Size    
                 15.5.1.1 Market Size (2020-2025)    
                 15.5.1.2 Market Forecast (2026-2036​)    
       15.5.2 Obesity Treatment- Market Size by Therapies    
                  15.5.2.1 Market Size by Therapies (2020-2025)               
                  15.5.2.2 Market Forecast by Therapies (2026-2036​)
        15.5.3 Obesity Treatment- Access and Reimbursement Overview 
   15.6    Market Scenario – United Kingdom
        15.6.1 Obesity Treatment - Market Size    
                  15.6.1.1 Market Size (2020-2025)    
                 15.6.1.2 Market Forecast (2026-2036​)
         15.6.2 Obesity Treatment- Market Size by Therapies    
                  15.6.2.1 Market Size by Therapies (2020-2025)
          15.6.2.2 Market Forecast by Therapies (2026-2036​)
        15.6.3 Obesity Treatment- Access and Reimbursement Overview 
    15.7    Market Scenario – Italy
          15.7.1 Obesity Treatment - Market Size
                  15.7.1.1 Market Size (2020-2025)    
                    15.7.1.2 Market Forecast (2026-2036​)    
      15.7.2 Obesity Treatment- Market Size by Therapies 
                  15.7.2.1 Market Size by Therapies (2020-2025)    
                   15.7.2.2 Market Forecast by Therapies (2026-2036​) 
         15.7.3 Obesity Treatment- Access and Reimbursement Overview 
    15.8    Market Scenario - Spain
          15.8.1 Obesity Treatment - Market Size
                 15.8.1.1 Market Size (2020-2025)
               15.8.1.2 Market Forecast (2026-2036​)    
         15.8.2 Obesity Treatment- Market Size by Therapies
                 15.8.2.1 Market Size by Therapies (2020-2025)    
                 15.8.2.2 Market Forecast by Therapies (2026-2036​)
        15.8.3 Obesity Treatment- Access and Reimbursement Overview 
    15.9    Market Scenario - Japan    
            15.9.1 Obesity Treatment - Market Size
                 15.9.1.1 Market Size (2020-2025)    
                 15.9.1.2 Market Forecast (2026-2036​)              
         15.9.2 Obesity Treatment- Market Size by Therapies
                  15.9.2.1 Market Size by Therapies (2020-2025)
                  15.9.2.2 Market Forecast by Therapies (2026-2036​)
         15.9.3 Obesity Treatment - Access and Reimbursement Overview 
16 Obesity Treatment - Recent Events and Inputs From Key Opinion Leaders
17 Obesity Treatment Market - SWOT Analysis    

   17.1    Strengths    
   17.2    Weaknesses    
   17.3    Opportunities    
   17.4    Threats    
18 Obesity – Strategic Recommendations        
19 Appendix

Obesity Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials